ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer - PubMed (original) (raw)
Review
ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer
D E Gerber et al. Clin Pharmacol Ther. 2015 May.
Abstract
The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.
© 2015 American Society for Clinical Pharmacology and Therapeutics.
Figures
Figure 1
Dramatic therapeutic effects of molecularly targeted therapies demonstrated in serial axial chest computed tomography images. (a) Radiographic response to epidermal growth factor receptor (EGFR) inhibition in patient with EGFR mutant non-small cell lung cancer (NSCLC) after 2 mo of treatment. (b) Ongoing radiographic response to anaplastic lymphoma kinase (ALK) inhibition in patient with ALK rearranged NSCLC after 6 mo of treatment.
Figure 2
ALCHEMIST schema.
Similar articles
- ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE. Govindan R, et al. Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354. Clin Cancer Res. 2015. PMID: 26672084 Free PMC article. Review. - Molecular oncology of lung cancer.
Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S. Toyooka S, et al. Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37. doi: 10.1007/s11748-010-0743-3. Epub 2011 Aug 18. Gen Thorac Cardiovasc Surg. 2011. PMID: 21850578 Review. - Personalized targeted therapy for lung cancer.
Wu K, House L, Liu W, Cho WCS. Wu K, et al. Int J Mol Sci. 2012;13(9):11471-11496. doi: 10.3390/ijms130911471. Epub 2012 Sep 13. Int J Mol Sci. 2012. PMID: 23109866 Free PMC article. Review. - Present and future molecular testing of lung carcinoma.
Dacic S, Nikiforova MN. Dacic S, et al. Adv Anat Pathol. 2014 Mar;21(2):94-9. doi: 10.1097/PAP.0000000000000012. Adv Anat Pathol. 2014. PMID: 24508692 Review. - EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
De Mello RA, Liu DJ, Aguiar PN, Tadokoro H. De Mello RA, et al. Recent Pat Anticancer Drug Discov. 2016;11(4):393-400. doi: 10.2174/1574892811666160803090944. Recent Pat Anticancer Drug Discov. 2016. PMID: 27491402 Review.
Cited by
- Design and analysis of umbrella trials: Where do we stand?
Ouma LO, Wason JMS, Zheng H, Wilson N, Grayling M. Ouma LO, et al. Front Med (Lausanne). 2022 Oct 12;9:1037439. doi: 10.3389/fmed.2022.1037439. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36313987 Free PMC article. - Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.
Tsao CC, Wu HH, Wang YF, Shen PC, Wu WT, Chen HY, Dai YH. Tsao CC, et al. Biomedicines. 2022 Jun 28;10(7):1539. doi: 10.3390/biomedicines10071539. Biomedicines. 2022. PMID: 35884843 Free PMC article. - Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.
Zhang Y, Zhang Y, Niu W, Ge X, Li X, Fan F, Li S, Liu H. Zhang Y, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Oct 28;46(10):1045-1053. doi: 10.11817/j.issn.1672-7347.2021.201009. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021. PMID: 34911833 Free PMC article. Chinese, English. - Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential.
Grayling MJ, Bigirumurame T, Cherlin S, Ouma L, Zheng H, Wason JMS. Grayling MJ, et al. BMC Rheumatol. 2021 Jul 2;5(1):21. doi: 10.1186/s41927-021-00192-5. BMC Rheumatol. 2021. PMID: 34210348 Free PMC article. - Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods.
Ouma LO, Grayling MJ, Zheng H, Wason J. Ouma LO, et al. Pharm Stat. 2021 Nov;20(6):990-1001. doi: 10.1002/pst.2119. Epub 2021 Mar 24. Pharm Stat. 2021. PMID: 33759353 Free PMC article.
References
- Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am. Soc. Clin. Oncol. Educ. Book. 2014:e353–e365. - PubMed
- Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008;26:3552–3559. - PubMed
- Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J. Clin. Oncol. 2014;32:780–787. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous